Website Search
Find information on spaces, staff, and services.
Catalog Search
Books
Handbook of brain tumor chemotherapy, molecular therapeutics, and immunotherapy
- Available as
- Online
Details
- Creator
- edited by Herbert B. Newton, MD, FAAN
- Format
- Books
- Language
- English
- Contributors
- Publication
-
- Second edition
- London, United Kingdom : Academic Press, an imprint of Elsevier, 2018
- ©2018
- Physical Details
-
- 1 online resource (1 volume (unpaged))
- ISBNs
- 0128121017, 9780128121009, 0128121009, 9780128121016
- OCLC
- on1030303042
- Includes index.
- Front Cover -- Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy -- Copyright -- Contents -- Contributors -- Section I: Pharmacological and Clinical Applications -- Chapter 1: Overview of Brain Tumor Epidemiology and Histopathology -- Epidemiology of Brain Tumors -- Pathology of Central Nervous System Tumors-Introduction -- Pathology of Tumors of Neuroepithelial Origin -- Pathology of Tumors of the Meninges -- Pathology of Primary CNS Lymphoma -- Pathology of Intracranial Germ Cell Tumors -- References -- Chapter 2: Clinical Pharmacology of Brain Tumor Chemotherapy -- Introduction -- Pharmacology and Drug Distribution -- Supportive Therapeutics -- Corticosteroids -- Gastric Acid Inhibitors -- Anticonvulsants -- Delivery of Chemotherapeutic Agents -- Continuous Infusion -- Intra-Arterial -- Interstitial -- Blood-Brain Barrier Disruption -- Chemotherapeutic Agents -- Alkylating Agents -- Nitrogen Mustards -- Nitrosoureas -- Procarbazine -- Platinum Compounds -- Temozolomide -- Natural Products -- Vinca Alkaloids -- Pyrimidine Analogs -- Purine Analogs -- Folic Acid Analogs -- Topoisomerase Inhibitors -- Camptothecin Derivatives -- Conclusions -- References -- Chapter 3: Antiepileptic Drugs and Chemotherapy: Potential Interactions and Impact on Treatment of Patients With Cancer -- Introduction -- Mechanism of Interaction Between AEDs and CTAs -- Phase I Interactions -- Phase II Interactions -- Other Potential Mechanisms of AED/CTA Interactions -- The Impact of AED-CTA Interactions -- EIAED Effects on Targeted Therapies -- AED Selection in Cancer Patients -- Expected Enzyme Induction Profile of New AEDs -- Changing From One AED to Another -- Conclusions -- Disclosure -- References -- Chapter 4: Brain Tumor Models for Cancer Therapy -- Rat Brain Tumor Models -- Blood-Brain Barrier in Rat Brain Tumor Models
- Local Delivery in Rat Brain Tumor Models -- Immunological Approaches in Rat Brain Tumor Models -- Chemotherapy and Boron Neutron Capture in Rat Brain Tumor Models -- Human Brain Tumor Xenograft Models -- Blood-Brain Barrier in Human Brain Tumor Xenograft Models -- Local Delivery in Human Brain Tumor Xenograft Models -- Chemotherapy in Human Brain Tumor Xenograft Models -- Angiogenesis in Brain Tumor Models -- References -- Chapter 5: Genomics and Proteomics in Neuro-Oncology -- Introduction -- RNA Expression Analysis -- DNA Methylation Analysis -- Disease Proteomics -- Preanalytic and Bioinformatic Considerations -- Tumor Expression Profiling: Medulloblastoma -- Molecular Basis and Genomic Subclassification of Medulloblastomas -- Tumor Expression Profiling: Glioma -- Drug Discovery and Targeting -- Summary -- References -- Further Reading -- Chapter 6: Chemotherapy Resistance -- Common Chemotherapeutic Agents in Gliomas -- DNA Repair and Chemotherapy Resistance -- Methylguanine Methyltransferase -- Histone Modification -- MicroRNAs and Long Noncoding RNAs -- DNA Mismatch Repair -- Nucleotide and Base Excision Repair -- Detoxification and Other Mechanisms of Resistance -- Glutathione-S-Transferase -- ATP-Binding Cassette or Multidrug Resistance Genes -- Summary -- References -- Chapter 7: Clinical Trial Design and Implementation in Neuro-Oncology -- Introduction -- Phase I trials -- Cytotoxic Agents -- Novel Agents -- Phase II Trials -- Cytotoxic Agents -- Novel Agents -- Limitations -- Phase III Trials -- Novel Designs -- Special Challenges of Brain Tumor Trials -- Drug Selection -- Neuropathology -- Endpoints -- Conclusions -- References -- Chapter 8: Biology of the Blood-Brain and Blood-Brain Tumor Barriers -- Cellular Anatomy of the Normal BBB -- Molecular Biology of BBB Tight Junctions
- Other Barriers, CSF, Brain Interstitial Fluid (ISF), Microdialysis -- Functions of the BBB -- Influx and Efflux Transport Systems -- Movement of Drugs Across the BBB, and Determinants of CNS Drug Concentration -- Recent Advances: BBB on a Chip -- Nanoparticle Carrier Systems -- Immunology and the BBB -- The ``Blood-Brain Tumor´´ Barrier -- Effects of Tumors and Tumor Treatments on the BBB -- Therapeutic Disruption or Circumvention of the BBB -- Conclusions -- References -- Further Reading -- Section II: Innovative Chemotherapy Delivery -- Chapter 9: Intraarterial Chemotherapy -- Introduction -- Pharmacological Rationale -- Single-Agent IA Chemotherapy of Newly Diagnosed Gliomas -- Combination IA Chemotherapy of Newly Diagnosed Gliomas -- Single-Agent IA Chemotherapy of Recurrent Gliomas -- Combination IA Chemotherapy of Recurrent Gliomas -- IA Chemotherapy for Primary CNS Lymphoma -- IA Chemotherapy for Brain Metastases -- Toxicity of IA Chemotherapy -- Conclusions -- References -- Chapter 10: Blood-Brain Barrier Disruption Chemotherapy -- Introduction -- Preclinical BBB Delivery Studies -- Clinical BBBD Technique -- Clinical BBBD Results -- Future BBBD Directions -- Summary -- References -- Chapter 11: Interstitial Chemotherapy and Polymer Drug Delivery -- Introduction -- Current Approaches and Outcomes in Treating Malignant Gliomas -- Barriers to Antineoplastics in the CNS -- Delivery Systems and Strategies for Brain Tumor-Targeted Delivery -- Development of Polymer-Based Local Delivery Systems -- Biodegradable Polymeric Wafers for the Delivery of BCNU -- Other Polymer-Based Delivery Methods -- Future Directions and Personalized Medicine -- Conclusion -- Disclosure Statement -- References -- Chapter 12: Intratumoral Chemotherapy and Convection-Enhanced Delivery -- Introduction -- General Principles -- Biophysical Principles -- Convective Delivery
- Distribution of Infusate -- Therapeutic Agents and Infusates Delivered -- Safety of CED -- Clinical Development -- Current Applications and Early Clinical Trials -- Conjugated Designer-Toxins and Fusion Proteins -- Chemotherapeutics -- Radiotoxic Agents -- Gene Therapy and Viral-Based Agents -- Review of Other Indications and Potentials -- Challenges -- Recent Advances and Future Directions -- Catheter Design -- Catheter Placement -- Infusate Delivery -- Conclusion -- References -- Chapter 13: Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue in Brain Tumors -- Introduction -- HS Trials -- Results of High-Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue (HDC/AuHCR) -- Medulloblastoma and Primitive Neuroectodermal Tumors (PNETs) -- Recurrent MB/PNET -- Newly Diagnosed MB/PNET -- Atypical Teratoid/Rhabdoid Tumors (ATRT) of the Brain -- Malignant Gliomas -- Recurrent Malignant Glioma -- Newly Diagnosed Malignant Glioma -- Ependymoma -- Recurrent Ependymoma -- Newly Diagnosed Ependymoma -- Central Nervous System Germ Cell Tumors (CNS-GCTs) -- Recurrent CNS-GCTs -- Newly Diagnosed CNS-GCTs -- Toxicities Related to HDC/AuHCR -- Acute (Short-Term) Toxicities -- Long-Term Toxicities -- Results of High-Dose Chemotherapy and Allotransplantation -- Conclusions -- References -- Chapter 14: CSF Dissemination of Primary Brain Tumors -- Introduction -- General Overview -- Clinical Presentation -- Diagnosis -- CSF Examination -- Neuroradiographic Studies -- Primary Brain Tumors -- Glioma -- Meningioma -- Primary CNS Lymphoma -- Ependymomas -- Primitive Neuroectodermal Tumor -- Germ Cell Tumor -- Treatment of NM -- Surgery -- Radiotherapy -- Chemotherapy -- Supportive Care -- Conclusions -- References -- Further Reading -- Chapter 15: Gene/Viral Treatment Approaches for Malignant Brain Cancer -- Introduction
- Delivery Methods for Gene Therapy -- Virus-Mediated Gene Delivery Vehicles -- Herpes Simplex Virus-1 -- Adenovirus -- Poliovirus -- Reovirus -- Measles Virus -- Other Viruses -- Nonviral Gene Delivery Vehicle (Nanoparticles) -- Stem Cells as a Gene Delivery Vehicle -- Neural Stem Cells -- Mesenchymal Stem Cells -- Advantages/Disadvantages of Delivery Vehicles -- The Types of Gene Therapy -- Prodrug Activation/Suicide Gene Therapy -- Herpes Simplex Virus Type 1 Thymidine Kinase (HSV/tk)/Ganciclovir -- Cytosine Deaminase/5-Fluorocytosine -- Cytochrome P450 -- Guanine Phosphoribosyltransferase -- Nitroreductase -- Carboxylesterase -- E. coli Purine Nucleoside Phosphorylase (E. coli PNP)/Purine Analogs -- Advantages/Disadvantages of Prodrug Activation/Suicide Gene Therapy -- Immunomodulatory and Cytokine-Based Gene Therapy -- Immune Checkpoints -- Cytokine Therapy -- Adaptive Cell Transfer of T Cells -- Vaccines -- Advantages/Disadvantages of Immunomodulatory and Cytokine-Based Gene Therapy -- Brain Tumor Hallmark Targeting Therapy -- Tumor-Suppressor Gene Therapy -- Antisense Therapy -- Antiangiogenic Gene Therapy -- Gene Therapies Involving Tumor Microenvironment -- Advantages/Disadvantages of Brain Tumor Hallmark Targeting Therapy -- Oncolytic Virotherapy -- Advantages/Disadvantages of Oncolytic Virotherapy -- Combinatory Therapies -- Clinical Trials Exploring Gene Therapy for Malignant Brain Tumors -- Discussion -- References -- Chapter 16: Nanoparticles as Therapeutic Agents for Patients With Brain Tumors -- Nanoparticles: Introduction to Basic Science and Bioengineering Principles -- Nanoparticle Types and Composition: Key Biological Considerations -- Selected Nanoparticles Designed for Clinical Use: Strategies for Killing Tumor Cells -- Preclinical Experimental Studies of Nanoparticles: Glioblastoma and Medulloblastoma
- Principles of Nanoparticle Delivery and Biodistribution In Vivo, Including the CNS